Presentation Guidance - Clinical

Each presentation is scheduled for 7 minutes with an additional 3 minutes for participant questions, interspersed with longer general discussion periods.

Rather than a program overview, each presenter is asked to focus specifically on any immunity issues, clinical, or potential subclinical inflammation, they have experienced in retinal gene therapy, including the impact on their studies, and how it was handled or adjusted for.

While no presentation may address all the points below, to promote a productive discussion, and to aid consistency between presentations, we have provided a list of considerations and questions pertinent to inflammation. We hope this will provide some guidance and direction for presentation.

Factors that may impact inflammation in Gene Therapy

Vector Design and CMC
Vector components and manufacturing methods can influence the immunogenicity of the IMP:

1. Type of vector, including serotype/pseudotype (e.g., ‘AAV8’ or ‘HIV-derived lenti pseudotyped with VSV-G’. For AAV if single-stranded or self-complementary)
2. General description of manufacturing process. Details such as potentially immunogenic components of production/storage media, titering method, and purification method
3. General description of quality control (e.g., for AAV: SDS-PAGE, endotoxin levels, empty to full capsid ratio, residual DNA content, etc.)
4. Characteristics of the insert (e.g., CpG content of gene, intron, promoter, enhancer, other transcriptional or translational control sequence)

Study Design:
1. What virus capsids are you using and at what viral load?
   a. Have you noted a difference in immune response related to viral load or volume injected?
2. Route of administration of vector:
   a. For intravitreal, selection rationale for needle gauge and length, placement of injection
   b. For subretinal, method of injection, including concentration and duration of exposure to agents such as triamcinolone during pars plana vitrectomy
3. Dose(s) and volume and if subretinal, whether single or multiple blebs
4. Age and gender of patient(s), and if null patients
5. For AAV, measurements of pre-existing neutralizing antibody (NAb) titers and decisions based on them
6. Any observations of intraocular or peri-orbital inflammation after injection
   a. What kind of reactions?
b. What is your monitoring schedule? How do you monitor?
c. When do the reactions start?
d. How long do they last?
e. How do you treat?
f. Any relationship observed between inflammation and efficacy or functional outcomes?

7. Do you use immunosuppression?
   a. Describe the protocol including agent name, dose, time to start
      immunosuppression, duration, timing, and route of administration
   b. Are all clinical sites using the same protocol?
   c. If not, why not?

8. Any clinical side effects of immunosuppression (e.g., weight gain, loss of sleep, cataracts, etc.)?

9. What kind of inflammatory events have you seen?
   a. How are they detected, i.e., clinical examinations, OCT, etc.?
   b. Do you measure functional assays of vision (e.g., BCVA, ERG).
   c. Do you measure changes in systemic or intraocular antibody response?
      Do they correlate with intraocular inflammation
   d. Do you collect anterior chamber or intravitreal fluid for antibodies or cytokines?

10. If inflammation is observed, how do you treat it?

11. What are the outcomes of those interventions?

12. Have you seen immune responses (or increased risk of an immune response)
    associated with surgical complications?
    a. How frequently are surgical/drug delivery complications seen?